These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 7602367)

  • 1. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
    Uziely B; Jeffers S; Isacson R; Kutsch K; Wei-Tsao D; Yehoshua Z; Libson E; Muggia FM; Gabizon A
    J Clin Oncol; 1995 Jul; 13(7):1777-85. PubMed ID: 7602367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
    Muggia FM; Hainsworth JD; Jeffers S; Miller P; Groshen S; Tan M; Roman L; Uziely B; Muderspach L; Garcia A; Burnett A; Greco FA; Morrow CP; Paradiso LJ; Liang LJ
    J Clin Oncol; 1997 Mar; 15(3):987-93. PubMed ID: 9060537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
    Cowens JW; Creaven PJ; Greco WR; Brenner DE; Tung Y; Ostro M; Pilkiewicz F; Ginsberg R; Petrelli N
    Cancer Res; 1993 Jun; 53(12):2796-802. PubMed ID: 8504422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer.
    Chao TC; Wang WS; Yen CC; Chiou TJ; Liu JH; Chen PM
    Cancer Invest; 2003; 21(6):837-47. PubMed ID: 14735687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
    Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
    Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
    Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
    Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
    Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
    Gabizon AA
    Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
    Lotem M; Hubert A; Lyass O; Goldenhersh MA; Ingber A; Peretz T; Gabizon A
    Arch Dermatol; 2000 Dec; 136(12):1475-80. PubMed ID: 11115157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
    Vasey PA; Kaye SB; Morrison R; Twelves C; Wilson P; Duncan R; Thomson AH; Murray LS; Hilditch TE; Murray T; Burtles S; Fraier D; Frigerio E; Cassidy J
    Clin Cancer Res; 1999 Jan; 5(1):83-94. PubMed ID: 9918206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
    Lambert-Falls R; Modugno S
    Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.
    Conley BA; Egorin MJ; Whitacre MY; Carter DC; Zuhowski EG; Van Echo DA
    Cancer Chemother Pharmacol; 1993; 33(2):107-12. PubMed ID: 8261569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer.
    Hubert A; Lyass O; Pode D; Gabizon A
    Anticancer Drugs; 2000 Feb; 11(2):123-7. PubMed ID: 10789595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
    El-Rayes BF; Ibrahim D; Shields AF; LoRusso PM; Zalupski MM; Philip PA
    Invest New Drugs; 2005 Jan; 23(1):57-62. PubMed ID: 15528981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
    Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
    Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.